Welcome to our dedicated page for JIN MED INTL LTD. SEC filings (Ticker: ZJYL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Jin Medical International Ltd. (ZJYL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on the Nasdaq Capital Market. Jin Medical files annual reports on Form 20-F and furnishes interim updates on Form 6-K, which together present information on its operations in wheelchair manufacturing, rehabilitation medical equipment, living aids products and related health and beauty devices.
Through these filings, investors can review unaudited condensed consolidated financial statements, management’s discussion and analysis of financial condition and results of operations, and details about the company’s manufacturing facilities in Changzhou, Taizhou and Chuzhou in China. Certain 6-K reports also describe material events, such as the launch of production at the Chuzhou intelligent manufacturing facility, appointment of independent directors and updates related to capital markets activities and registration statements on Form F-3.
Listing-related disclosures, including Nasdaq notifications about minimum bid price requirements and shareholder distribution rules, are typically reported via 6-K filings or referenced in company press releases. These documents help readers understand Jin Medical’s compliance status, potential remedial actions and associated timelines. Corporate governance information, such as committee assignments and director backgrounds, can also appear in these reports.
On Stock Titan, AI-powered tools summarize lengthy filings so users can quickly identify key points in Jin Medical’s 20-F and 6-K submissions, including segment information, risk discussions and updates on rehabilitation and assistive technology initiatives. Real-time integration with the SEC’s EDGAR system allows timely access to new filings, while structured views of exhibits and XBRL data support deeper analysis of financial and operational trends relevant to Jin Medical’s role in the surgical and medical instrument manufacturing sector.
Jin Medical International Ltd. (NASDAQ: ZJYL) filed a Form 6-K announcing the appointment of Dr. James Jiayuan Tong, age 51, as an Independent Director. Effective 20 June 2025, Dr. Tong becomes Chair of the Nominating & Corporate Governance Committee and joins the Audit and Compensation Committees, thereby increasing the proportion of independent oversight on all three key board panels.
Dr. Tong brings more than 20 years of cross-border experience in finance, investment banking, healthcare and academic research. Recent roles include founder of ThorBay Holdings (2022-present) and Venture Partner at Korea Investment Partners (2019-2022) with a focus on oncology, AR/VR, AI healthcare, medical devices and pre-IPO strategy. He has previously served as CFO and venture partner in both public and private companies, and has managed SEC compliance and M&A processes—skills directly relevant to committee responsibilities. Dr. Tong holds an M.D. from Peking University Health Science Center (1996) and a Ph.D. in Neuroscience from Stony Brook University (2001). There are no family relationships or related-party transactions requiring disclosure under Regulation S-K Item 404. The filing is expressly not incorporated by reference into other SEC filings.
The addition of an experienced, fully independent director with deep financial and healthcare expertise should strengthen Jin Medical’s governance framework and may enhance investor confidence; however, the filing contains no financial data or immediate operational changes.